SURPASS-4 trial finds tirzepatide associated with superior reductions in HbA1c and weight compared to insulin glargine in type 2 diabetes

The once-weekly dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist was associated with significant declines in HbA1c & weight versus titrated insulin glargine; e.g. for the highest dose, 2.58% reduction in HbA1c and 11.7kg decrease in weight at 52 weeks

Source:

Biospace Inc.